267 Dalbavancin for the treatment of Streptococcal Skin Infections

por Puttagunta, Sailaja, Dunne, Michael
Publicado 2014

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies

por Dunne, Michael W, Sahm, Dan, Puttagunta, Sailaja
Publicado 2015

1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determ...

por Dunne, Michael, Aronin, Steven, Dunzo, Elise, Puttagunta, Sailaja
Publicado 2018

1527. The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outco...

por Dunne, Michael, Gupta, Vikas, Aronin, Steven, Puttagunta, Sailaja
Publicado 2018

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)

por Aronin, Steven I, Dunne, Michael W, Gupta, Jayanti, Puttagunta, Sailaja
Publicado 2023

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies

por Puttagunta, Sailaja, Boucher, Helen, Talbot, George, Wilcox, Mark, Dunne, Michael
Publicado 2014

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program

por Puttagunta, Sailaja, Wilcox, Mark, Boucher, Helen, Talbot, George, Dunne, Michael
Publicado 2014

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates

por Puttagunta, Sailaja, Aronin, Steven I., DiFranco-Fisher, Jeanna, Koeth, Laura
Publicado 2023

A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 pa...

por Quartin, Andrew A, Scerpella, Ernesto G, Puttagunta, Sailaja, Kett, Daniel H
Publicado 2013

1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection

por Puttagunta, Sailaja, Aronin, Steven, Huband, Michael, Flamm, Robert K, Dunne, Michael
Publicado 2018

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects

por Scoble, Patrick J., Owens, Robert C., Puttagunta, Sailaja, Yen, Mark, Dunne, Michael W.
Publicado 2015

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

por Dunne, Michael W., Talbot, George H., Boucher, Helen W., Wilcox, Mark, Puttagunta, Sailaja
Publicado 2015

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

por Dunne, Michael W., Puttagunta, Sailaja, Giordano, Philip, Krievins, Dainis, Zelasky, Michael, Baldassarre, James
Publicado 2016

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection

por Rappo, Urania, Nguyen, H. Bryant, Puttagunta, Sailaja, Ojaimi, Caroline, Akinapelli, Karthik, Dunne, Michael W.
Publicado 2020

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales

por Dunne, Michael W., Puttagunta, Sailaja, Aronin, Steven I., Brossette, Stephen, Murray, John, Gupta, Vikas
Publicado 2022

The Ability of Virulence Factor Expression by Pseudomonas aeruginosa to Predict Clinical Disease in Hospitalized Patients

por Ledizet, Michel, Murray, Thomas S., Puttagunta, Sailaja, Slade, Martin D., Quagliarello, Vincent J., Kazmierczak, Barbara I.
Publicado 2012

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs

por Gonzalez, Pedro Luis, Rappo, Urania, Akinapelli, Karthik, McGregor, Jennifer S, Puttagunta, Sailaja, Dunne, Michael W
Publicado 2018

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

por Gonzalez, Pedro L., Rappo, Urania, Akinapelli, Karthik, McGregor, Jennifer S., Puttagunta, Sailaja, Dunne, Michael W.
Publicado 2021

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program

por Maher, Joshua M, Huband, Michael D, Blankers, Christopher G, Puttagunta, Sailaja, Aronin, Steven I, Castanheira, Mariana
Publicado 2023

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

por Rappo, Urania, Dunne, Michael W., Puttagunta, Sailaja, Baldassarre, James S., Su, Shengfang, Desai-Krieger, Daksha, Inoue, Megumi
Publicado 2019